Related Experiment Video

Updated: May 22, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Targeting protein-tyrosine phosphatases in breast cancer

Nicola Aceto, Mohamed Bentires-Alj

    Oncotarget
    |May 26, 2012
    PubMed

    Insights

    Protein tyrosine phosphatases (PTPs) are key in breast cancer. SHP2 and PTP1B show promise as therapeutic targets for breast cancer and diabetes treatment.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • Protein tyrosine phosphatases (PTPs) play critical roles in cellular signaling pathways.
    • Dysregulation of PTPs is implicated in the initiation, progression, and maintenance of breast cancer.
    • Specific PTPs, such as SHP2 and PTP1B, are emerging as significant targets for therapeutic intervention.

    Discussion:

    • SHP2 and PTP1B are identified as potential targets for breast cancer treatment and prevention.
    • PTP1B also holds importance in the context of diabetes management.
    • The organ-dependent nature of PTP involvement necessitates careful consideration for targeted therapies.

    Key Insights:

    • PTPs are actively involved in breast cancer pathogenesis.
    • Targeting specific PTPs like SHP2 and PTP1B may offer novel therapeutic strategies.
    • Understanding the differential roles of PTPs is crucial for effective drug development.

    Outlook:

    • Future research should explore the involvement of other PTPs in tissue homeostasis and cancer.
    • Investigating signaling networks affected by PTP inactivation is essential.
    • This line of inquiry promises to uncover novel PTP-regulated mechanisms and advance cancer pathway understanding.

    More Related Videos

    Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

    Development and Application of Rapamycin-regulated Tyrosine Phosphatases

    Published on: September 6, 2024

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    Receptor Tyrosine Kinases01:26

    Receptor Tyrosine Kinases

    Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...